Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Neusoft Medical System’s PET Obtains U.S. FDA Authentication

This article was originally published in PharmAsia News

Executive Summary

Neusoft Medical System, a subsidiary of Neusoft Group, has received the go-ahead from U.S. FDA to market its positron emission computer tomography technology in the U.S. It represents China's first corporation capable of producing PET technology and marketing it globally. At present, China spends hundreds of million dollars each year importing medical equipment. About 70 percent of the local high-end medical device market is monopolized by MNCs; for instance, GE, Siemens and Philips have cornered the CT and MR sector. Neusoft Medical System's PET technology not only fills a gap in the country's high-end medical equipment manufacturing, but also marks a milestone in reforming the trade structure of the healthcare industry. The company will sell its first machine to the U.S. this July. (Click here for more - Chinese Language)
Advertisement
Advertisement

Related Content

Advertisement
UsernamePublicRestriction

Register

SC072110

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel